SGLT-2 Inhibitor and ARB Combination for Hypertension and Diabetes

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current antidiabetic and antihypertensive therapies face challenges in achieving synergistic blood pressure lowering effects and patient compliance due to the need for multiple medications, particularly in patients with both hypertension and diabetes.

Innovation Solution

A pharmaceutical composition combining an SGLT-2 inhibitor and an angiotensin receptor blocker (ARB) is formulated to enhance blood pressure lowering effects and patient compliance by co-administering these agents in a single formulation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If multiple medications are administered to patients with both hypertension and diabetes, then the treatment coverage is improved, but patient compliance deteriorates

Engineering Contradiction:

Improvetreatment coverageVSAvoidpatient compliance

Core Design Contradiction:

Adaptability or versatilityVSEase of operation

Solution Approach 1:

The patent combines SGLT-2 inhibitor and ARB into a single pharmaceutical composition, allowing patients to take one medication that simultaneously addresses both hypertension and diabetes, thereby improving compliance while maintaining comprehensive treatment coverage

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The pharmaceutical composition is designed to perform multiple therapeutic functions - lowering blood pressure through ARB mechanism and controlling blood glucose through SGLT-2 inhibition mechanism - within a single agent, making it universally effective for patients with both conditions

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If SGLT-2 inhibitor and ARB are co-administered, then the blood pressure lowering effect is improved, but the complexity of medication regimen worsens

Engineering Contradiction:

Improveblood pressure lowering effectVSAvoidmedication regimen complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent merges SGLT-2 inhibitor and ARB into a single pharmaceutical composition, maintaining the synergistic blood pressure lowering effect of both agents while simplifying the medication regimen from multiple separate medications to one combined formulation

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS10980822B2Medicinal composition comprising SGLT-2 inhibitor and angiotensin receptor blocker

Publication Date: 2021.04.20 AUTOTELIC BIO INC

AI summary

Provided is a pharmaceutical composition comprising an antidiabetic agent and an antihypertensive agent as active ingredients.